THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [3.31]-CMP2 ID: TIP-MED-000272 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Sumatriptan & Rizatriptan (Acute Migraine 5-HT1B/1D Agonists)

Active Ingredient / Scientific Identity: Sumatriptan & Rizatriptan • Class: Non-Selective Beta-1 & Beta-2 Adrenoceptor Blocker (Schedule H | NLEM 2022)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Sumatriptan & Rizatriptan (Acute Migraine 5-HT1B/1D Agonists) ([3.31]-CMP2 | ID: TIP-MED-000272) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/3-31-cmp2-sumatriptan-rizatriptan-acute-migraine-5-ht1b-1d-ago/
Generic / Entity NameSumatriptan & Rizatriptan (Acute Migraine 5-HT1B/1D Agonists) ([3.31]-CMP2)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassNon-Selective Beta-1 & Beta-2 Adrenoceptor Blocker (Schedule H | NLEM 2022)
Available Dosage FormsStandard approved strengths (refer to comparative context)
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Caution in severe CKD. Hepatic: High first-pass metabolism — start at 20 mg/day in cirrhosis and titrate slowly by hea
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Sumatriptan & Rizatriptan (Acute Migraine 5-HT1B/1D Agonists) (TIP-MED-000272, Reference Code [3.31]-CMP2) is classified under Cardiovascular & Antithrombotic Medicines (Ch 03) as a Non-Selective Beta-1 & Beta-2 Adrenoceptor Blocker (Schedule H | NLEM 2022). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed per approved Author Decision DEC-08 (Option 8A; displaced HTML [11.28]). Acute migraine abortive triptans (Suminat 50/100 mg, Rizact 5/10 mg); Propranolol inhibits MAO-A metabolism of Rizatriptan, increasing Rizatriptan AUC by 70% (cap Rizatriptan at 5 mg single dose with Propranolol!).
Co-indexed per approved Author Decision DEC-08 (Option 8A; displaced HTML [11.28]). Acute migraine abortive triptans (Suminat 50/100 mg, Rizact 5/10 mg); Propranolol inhibits MAO-A metabolism of Rizatriptan, increasing Rizatriptan AUC by 70% (cap Rizatriptan at 5 mg single dose with Propranolol!).
Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)
Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

Co-indexed per approved Author Decision DEC-08 (Option 8A; displaced HTML [11.28]). Acute migraine abortive triptans (Suminat 50/100 mg, Rizact 5/10 mg); Propranolol inhibits MAO-A metabolism of Rizatriptan, increasing Rizatriptan AUC by 70% (cap Rizatriptan at 5 mg single dose with Propranolol!).

4. Therapeutic Indications & Evidence-Supported Uses

  • Migraine prophylaxis, essential tremor, thyrotoxicosis / thyroid storm symptom control, portal hypertension (oesophageal variceal bleed prophylaxis), performance/somatic anxiety, infantile haemangioma

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-08 (Option 8A; displaced HTML [11.28]). Acute migraine abortive triptans (Suminat 50/100 mg, Rizact 5/10 mg); Propranolol inhibits MAO-A metabolism of Rizatriptan, increasing Rizatriptan AUC by 70% (cap Rizatriptan at 5 mg single dose with Propranolol!).

Administration & Meal Timing: Take IR before meals; take LA/TR capsules whole at a consistent time daily | Morning & Evening (or Bedtime for LA once daily)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [3.31].
Metabolism & Biotransformation:
Renal: Caution in severe CKD. Hepatic: High first-pass metabolism — start at 20 mg/day in cirrhosis and titrate slowly by heart rate
Elimination & Renal Adjustment:
Renal: Caution in severe CKD. Hepatic: High first-pass metabolism — start at 20 mg/day in cirrhosis and titrate slowly by heart rate
Hepatic Impairment Considerations:
Renal: Caution in severe CKD. Hepatic: High first-pass metabolism — start at 20 mg/day in cirrhosis and titrate slowly by heart rate

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • STRICTLY CONTRAINDICATED in asthma, COPD, bronchospasm, bradycardia (<50 bpm), 2nd/3rd-degree AV block, uncompensated HF, and brittle insulin-dependent diabetes (blunts glycogenolysis & masks hypoglycaemia!)

Key Clinical Precautions: Renal: Caution in severe CKD. Hepatic: High first-pass metabolism — start at 20 mg/day in cirrhosis and titrate slowly by heart rate

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Fatigue, cold extremities, vivid dreams/insomnia (lipophilic — crosses BBB), bradycardia, dizziness
  • Acute life-threatening bronchospasm in asthmatics, prolonged severe hypoglycaemia, heart block, rebound angina if stopped abruptly
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • LASA ALERT: Ciplar (Propranolol) vs
    • Ciprobid/Ciplox (Ciprofloxacin)! CYP1A2/2D6 inhibitors (Fluvoxamine, Ciprofloxacin) increase levels; Rizatriptan dose must be halved (max 5 mg) when co-prescribed with Propranolol!

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [3.31].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: Never give to anyone with asthma or wheezing; verify 'Ciplar' vs 'Ciplox' at counter; taper gradually when discontinuing
    • Meal & Clock Timing Instruction: Take IR before meals; take LA/TR capsules whole at a consistent time daily (Morning & Evening (or Bedtime for LA once daily))
    • Missed Dose Protocol: Skip if close to next dose; never double dose or stop abruptly
    • Geriatric Dispensing Pearl: Lipophilic beta-blocker crosses BBB causing nightmares, lethargy, and falls in elderly; prefer lower doses

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: IR Tablets: 10 mg, 20 mg, 40 mg; Long-Acting (LA/TR) Tablets/Capsules: 20 mg, 40 mg, 80 mg

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

    ← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
    Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/3-31-cmp2-sumatriptan-rizatriptan-acute-migraine-5-ht1b-1d-ago/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.